{"product_id":"global-molecular-diagnostics-point-of-care-market-growth-status-and-outlook-2023-2029","title":"Global Molecular Diagnostics Point of Care Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Molecular Diagnostics Point of Care Market Growth (Status and Outlook) 2023-2029\u003cbr\u003e\nThe global Molecular Diagnostics Point of Care market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eUnited States market for Molecular Diagnostics Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eChina market for Molecular Diagnostics Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eEurope market for Molecular Diagnostics Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal key Molecular Diagnostics Point of Care players cover Abbott Laboratories, Abaxis, Bayer Healthcare, Bio-Rad Laboratories, Becton Dickinson and Company, Binx Health, BioMerieux, Co-Diagnostics and DanaherCorporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.\u003c\/p\u003e\n\n\u003cp\u003eThe Molecular Diagnostics Point of Care enables physicians to improve the standard of care by combining rapid diagnosis with treatment decisions during the first patient visit.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Molecular Diagnostics Point of Care Industry Forecast” looks at past sales and reviews total world Molecular Diagnostics Point of Care sales in 2022, providing a comprehensive analysis by region and market sector of projected Molecular Diagnostics Point of Care sales for 2023 through 2029. With Molecular Diagnostics Point of Care sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Diagnostics Point of Care industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Molecular Diagnostics Point of Care landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Diagnostics Point of Care portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Diagnostics Point of Care market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Diagnostics Point of Care and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Diagnostics Point of Care.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Molecular Diagnostics Point of Care market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nAssays and Kits\u003cbr\u003e\nInstruments and Analyzers\u003cbr\u003e\nSoftware and Services\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nTumor\u003cbr\u003e\nHematology\u003cbr\u003e\nEndocrinology\u003cbr\u003e\nInfectious Disease\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nAbaxis\u003cbr\u003e\nBayer Healthcare\u003cbr\u003e\nBio-Rad Laboratories\u003cbr\u003e\nBecton Dickinson and Company\u003cbr\u003e\nBinx Health\u003cbr\u003e\nBioMerieux\u003cbr\u003e\nCo-Diagnostics\u003cbr\u003e\nDanaherCorporation\u003cbr\u003e\nDako\u003cbr\u003e\nF. Hoffmann\u003cbr\u003e\nOraSure Technologies\u003cbr\u003e\nRoche Diagnostics\u003cbr\u003e\nNipro Diagnostics\u003cbr\u003e\nGenestat\u003cbr\u003e\nMeridian Bioscience\u003cbr\u003e\nMolbio Diagnostics\u003cbr\u003e\nSiemens Healthcare\u003cbr\u003e\nThermo Fisher Scientific\u003cbr\u003e\nVisby Medical\u003cbr\u003e\nWuhan Easy Diagnosis Biomedicine\u003cbr\u003e\nBeijing Tiandz\u003cbr\u003e\nBeijing Content\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 123 Pages \/ MCW16237059","offer_id":47652354785586,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-molecular-diagnostics-point-of-care-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}